Six months into 2019 and the medtech sector has already surpassed 2018’s M&A total. Deals worth more than $29.5bn have been closed so far this year, swelled by Johnson & Johnson’s purchase of surgical robotics group Auris Health and the sale of healthcare records company Athenahealth to private equity: both these transactions weighed in at more than $5bn.
Even so, the total is far short of 2017’s, which almost cracked $100bn. The mean price paid, though, is creeping back up to 2017 levels: the 39 mergers with disclosed value were worth $755m each on average, more than twice as much as last year.
|Medtech acquisitions of the past five years|
|Deal completion date||Deal value ($bn)||No of deals||No of deals with known value||Average deal size ($m)|
Much of the activity here is at the top end. Eight multibillion-dollar deals have closed so far this year, more than in all of 2018, but the number of acquisitions worth less than $1bn is way down. 16 deals in this size bracket have been closed so far in 2019. Extrapolating this out to the next six months would give a 2019 total of 32, rather less than the 40 seen in 2018 or the 41 a year earlier.
An inkling of the reason for this concentration of larger mergers is given by a look at the type of companies being bought. The four largest buys this year all concern businesses that supply hospitals, a fairly commoditised space where competition is fierce and generally price-based. The need for large groups to build scale to broaden their offering and make themselves appealing to often cash-strapped customers is clear, and consolidation the answer.
|No of deals closed by size bracket, past five years|
|Note: only includes deals with known value. Source: EvaluateMedTech.|
The other notable point is the continuation of the trend of private equity increasingly involving itself in medical technology. Last year four of the top 10 transactions saw medtech companies or business units fall to private equity shops, and so far this year two such deals have occurred.
Flush with cash and the debt financing permitted by low interest rates, private equity is being more active in acquiring companies and carve-outs across many sectors, not just medtech. But heath tech groups can be particularly appealing: unlike natural resources, for example, the product supply is not finite, nor is it subject to increasing regulatory strictures.
The developed world’s ageing population means demand for devices is only going up, and investment groups are often convinced that they can increase efficiency, curbing spending and making the kind of hard choices that might be better made away from the scrutiny that attends listed companies.
|Top 10 deals closed in H1 2019|
|Completion date||Acquirer||Target||Value ($m)||M&A focus|
|Apr 1||Johnson & Johnson||Auris Health||5,750||Endoscopy; general & plastic surgery|
|Feb 11||Veritas Capital and Elliott Management||Athenahealth||5,700||General hospital & healthcare supply; healthcare IT|
|Feb 22||Colfax||DJO Global||3,150||Orthopaedics; physical medicine|
|Apr 1||Fortive||Advanced Sterilization Products business of Johnson & Johnson||2,800||Endoscopy; general hospital & healthcare supply|
|Feb 21||Fresenius Medical Care||Nxstage Medical||2,000||Blood; nephrology|
|Mar 31||Montagu Private Equity and Astorg||Nemera||1,150||Drug delivery|
|Feb 1||3M||M*Modal||1,000||Healthcare IT|
|Jan 31||Sonic Healthcare||Aurora Diagnostics||540||In vitro diagnostics|
|Jun 11||Boston Scientific||Vertiflex||465||Orthopaedics|
|Jan 29||Boston Scientific||Millipede||450||Cardiology|
Some acquisitions were motivated by medtech companies attracted by their target’s technology, rather than investment groups’ solely financial considerations.
Dialysis giant Fresenius Medical Care closed its takeout of Nxstage Medical, maker of portable and home-based blood filtration machines. The $2bn deal hit antitrust obstacles, as had been widely expected, but eventually closed in February after Fresenius divested Nxstage’s bloodline tubing set business (A long road to the next stage for Fresenius, February 27, 2019).
And Boston Scientific closed not one but two technology-specific bolt-on deals as it ramps up its inorganic growth strategy to better compete with its larger rivals. The acquisition of Millipede, which makes a device to repair the mitral valve, will enable Boston to go up against Abbott, though that company’s MitraClip is well established on the market. And its purchase of spine implant developer Vertiflex will boost Boston’s orthopaedics offering and allow it to square up to groups like Medtronic and Stryker.